Skip to main content
. Author manuscript; available in PMC: 2015 Apr 28.
Published in final edited form as: J Clin Pharmacol. 2013 Nov 19;54(1):87–96. doi: 10.1002/jcph.208

Figure 4.

Figure 4

Figure 4

Figure 4

Efavirenz simulated plasma concentration at 14 hours following administration of a) 600, b) 400, and c) 200 mg daily. Median and 95% prediction interval of simulated concentrations are displayed for each CYP2B6 genotype; Dark Gray (*1/*1), Light Gray (*1/*6) and Whtie (*6/*6).